• InterMune Inc., of Brisbane, Calif., reported preliminary fourth-quarter net sales of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) totaling about $2.8 million. The drug, which gained approval in Europe last year, has been launched in Germany, with about 612 patients prescribed since mid-September. InterMune plans to launch Esbriet in France, Spain and Italy in the second quarter and in the UK in October.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST